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E-mail address: grzegorz@cmdik.pan.pl (G.A. CzapThe aim of the present study was to analyse the alterations of Cyclin dependent kinase 5 (Cdk5)
expression and phosphorylation in PC12 cells overexpressing Amyloid precursor protein (APP).
Our results demonstrated enhanced cell death and increased levels of mRNA for the Cdk5 gene in
APP-transfected cells. Signiﬁcantly decreased phosphorylation of Cdk5 at Tyr15 was observed in
APPsw cells, which is responsible for a reduction in Cdk5 activity. Cdk5-dependent phosphorylation
of Glycogen synthase kinase-3b (Gsk-3b) at Ser9 was also decreased, which can lead to the increase of
Gsk-3b activity and hyperphosphorylation of MAP tau. Our results demonstrate for the ﬁrst time, a
deregulation of Cdk5 phosphorylation in APP-transfected cells.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Amyloid beta (Ab) remains at the centre of Alzheimer’s disease
(AD) research as a primary factor that is responsible for the activa-
tion of the cascade leading to the progression of neurodegenera-
tion. Among the many other processes observed in AD
pathophysiology, disturbances of calcium homeostasis and the
hyperphosphorylation of MAP tau seem to be important compo-
nents of this pathogenic cascade. Cyclin-dependent kinase 5
(Cdk5) may functionally link these elements with Ab-related toxic-
ity. Cdk5 belongs to the family of proline-directed serine/threonine
kinases and plays a critical role in the development of the central
nervous system [1]. The activation of Cdk5 is triggered by the bind-
ing of the regulatory subunits, p35 (Cdk5r1) or p39 (Cdk5r2), and
modulated by phosphorylation at Tyr15 and Ser159 [2]. Proteins
p35 and p39 contain amino-terminal-located highly-conserved
myristylation signal motifs that direct the active complex to cellu-
lar membranes. During the deregulation of calcium homeostasis,
Ca-dependent calpains proteolyse p35 and p39 that leads to the
formation of p25 and p29 [3–5]. The truncated proteins p25 and
p29 are denuded of the membrane anchorage sequence that causes
the mislocalisation of the active Cdk5 complex and therefore, alters
the substrate preferences of Cdk5 [6]. Due to the increased stability
of p25 and p29, the binding of these truncated forms evokes achemical Societies. Published by E
ski).prolonged overactivation of Cdk5, which has been demonstrated
in many neurotoxic conditions, such as AD, Parkinson’s disease,
brain ischemia, alcohol-induced neurodegeneration [7–12]. It has
been observed in cellular experimental models that Ab stimulates
the cleavage of p35 to p25, and the inhibition of Cdk5 reduces
Ab-evoked cell death [13]. Also recent studies in vivo have demon-
strated the calpain-dependent deregulation of Cdk5 activity in a
mouse model of AD [14]. Moreover, post-mortem analysis of brain
preparations of AD patients indicates an accumulation of p25 and
an increase of Cdk5 activity [15,16].
Many Cdk5 substrates, like MAP tau, APP, NMDAR, p53, Gsk-3b,
STAT1/3, are related to AD-related pathomechanisms. It was dem-
onstrated previously that increased activity of Cdk5/p25 may be
responsible for the hyperphosphorylation of MAP tau, the destabil-
isation of the cytoskeleton and neuronal death [8]. The overexpres-
sion of p25 or p35 induces the phosphorylation of APP at Thr668,
which signiﬁcantly increases the secretion of Ab peptides [6]. The
increased activity of Cdk5may also be responsible for the transcrip-
tional activation of the BACE1 promoter and in consequence for en-
hanced amyloidogenesis [17]. However, other studies on the role of
Cdk5 in the pathomechanisms of AD have produced contradictory
results. The inhibition of Cdk5 leads to enhanced Ab production
[18]. In APP knock-out mice, the APP level is inversely correlated
with Cdk5 activity and an increase in Cdk5 activity may be respon-
sible for the aberrant tau phosphorylation in neurotoxic conditions
[19]. Therefore, the deregulation of Cdk5 activity may be a poten-
tially important factor in the Ab-evoked neurotoxic cascade.lsevier B.V. All rights reserved.
Fig. 1. The effect of APP-transfection on cell viability. The effect of APP-transfection
on cell death was estimated using the LDH assay. PC12, APPwt and APPsw cells
were incubated in low-serum medium for 48 h, and the LDH leakage assay was
performed as described in Section 2. Data represent the mean value ± S.E.M. for 6–7
independent experiments. ⁄⁄P < 0.01, compared to control cells; ##P < 0.01 com-
pared to APPwt cells using a one-way ANOVA followed by Newman–Keuls test.
1244 G.A. Czapski et al. / FEBS Letters 585 (2011) 1243–1248The aim of the present study was to analyse the effect of the
overexpression of APP on Cdk5 expression, phosphorylation state
and activity. Our results indicated that, despite the increased
expression of Cdk5 in APP-transfected cells, alterations of Cdk5
phosphorylation led to a decrease in Cdk5 activity that may be
responsible for the deleterious overactivation of Gsk-3b.
2. Materials and methods
2.1. Chemicals
The following antibodies were used in the current study: anti-
Cdk5, anti-phospho-Tau(Ser396) (Cell Signaling, Beverly, MA,
USA), anti-phospho-Cdk5(Tyr15), anti-phospho-Cdk5(Ser159),
anti-Gsk-3b, anti-phospho-Gsk-3b(Ser9) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), anti-GAPDH (Sigma–Aldrich, St. Louis, MO,
USA), anti-actin (MP Biomedicals, Solon, OH), anti-mouse IgG (GE
Health Care UK, Little Chalfont, Buckinghamshire, UK), anti-rabbit
IgG (Sigma–Aldrich). An LDH-cytotoxicity Assay Kit II was pur-
chased from BioVision (Mountain View, CA, USA). Reagents for re-
verse transcription (High Capacity RNA-to-cDNA Master Mix) and
PCR (Gene Expression Master Mix) were from Applied Biosystems
(Applied Biosystems, Foster City, CA, USA). Dulbecco’s Modiﬁed Ea-
gle’s Medium (DMEM), Fetal Bovine Serum (FBS), Horse Serum
(HS), penicillin, streptomycin, G418, glutamine, Deoxyribonuclease
I, 3-(4,5-dimethyl-2-tiazolilo)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT), Tri-reagent, DTT, polyethylenoimine (PEI), DMSO
and all other common reagents were from Sigma–Aldrich.
2.2. Cell culture
Rat pheochromocytoma PC12 cells [20] and their derivative
clones stably expressing human APP were a kind gift from Dr.
W.E. Mueller (University of Frankfurt, Frankfurt am Main, Ger-
many). Three PC12 cell lines were used: (1) cells empty vector-
transfected (PC12), (2) cells APPwt – transfected with human
wild-type APP gene, and (3) cells APPsw – transfected with a hu-
man APP gene with the Swedish mutated (K670M/N671L) form
of the human APP695 isoform [21]. All cell lines were cultured in
DMEM supplemented with 10% heat-inactivated FBS, 5% heat-inac-
tivated horse serum, 2 mM L-glutamine, 50 U/ml penicillin and
50 lg/ml streptomycin in a 5% CO2 atmosphere at 37 C. Stably
transfected cells were maintained in media containing 400 lg/ml
G418.
2.3. Cytotoxicity assays
For analysis of the effect of transfection on mitochondrial func-
tion and cell survival, an MTT assay was performed. Equal cell
numbers were cultured in a 24-well PEI-coated plate, and after
48 h, the medium was changed to serum-free DMEM. MTT
(0.25 mg/ml) was added and cells were incubated for 2 h. The med-
ium was removed, the cells were dissolved in DMSO, and the
absorbance at 595 nm was measured.
For the analysis of necrotic cell death, an LDH assay was per-
formed using a commercial LDH-cytotoxicity Assay Kit II (BioVi-
sion) according to manufacturer’s instructions.
2.4. Western immunoblotting
Cells were washed three times with ice-cold PBS, lysed with
Laemmli buffer and denatured at 95 C for 5 min. Protein levels
were determined using the Lowry method after acetone precipita-
tion. After standard 10% SDS–PAGE, proteins were transferred to a
PVDF membrane and used for immunochemical detection in stan-
dard conditions.2.5. PCR
Cells were washed twice with ice-cold PBS, scraped from the
culture dish and centrifuged brieﬂy (3 min, 1000g). RNA was iso-
lated from the cell pellet using TRI-reagent according to the man-
ufacturer’s protocol (Sigma–Aldrich). Digestion of DNA
contamination was performed using DNase I according to the man-
ufacturer’s protocol (Sigma–Aldrich). RNA quantity and quality
was controlled by spectrophotometric analysis and gel electropho-
resis. Reverse transcription was performed using a High Capacity
cDNA Reverse Transcription Kit according to the manufacturer’s
protocol (Applied Biosystems). Quantitative PCR was performed
on an ABI PRISM 7500 apparatus using pre-developed TaqMan
Gene Expression Assays (Applied Biosystems) according to the
manufacturer’s instructions: Cdk5-Rn00590045_m1; Cdk5r1-
Rn02132948_s1; Cdk5r2-Rn01400841_s1; App-Rn00570673_m1;
APP-Hs01552286_m1; Ptgs2-Rn01483828_m1; Fosb-
Rn00500401_m1; Actb-4352340E; Gusb-Rn00566655_m1; Tbp-
Rn01455648_m1. Actb, Gusb and Tbp were used as reference
genes. Actb was selected and used in all studies. The relative levels
of mRNA were calculated using the DDCt method.
2.6. Statistics
Statistical analysis was performed with Graph Pad Prism ver-
sion 5.0 (Graph Pad Software, San Diego, CA) using a one-way anal-
ysis of variance (ANOVA) with Newman–Keuls post-hoc test. Data
are presented as means ± S.E.M. P < 0.05 was considered
signiﬁcant.
3. Results
3.1. APP-transfected cells exhibited a decreased survival rate
To study the effect of the prolonged inﬂuence of enhanced
amounts of Ab on cells, we compared the cells transfected with hu-
man wild-type or Swedish mutant APP gene to control cells trans-
fected with an empty vector. We analysed the amount of dead cells
using an LDH assay. As presented on Fig. 1, transfection with the
APP gene evoked an increase in the percent of dead cells from
13.65 ± 0.75% in control to 18.72 ± 1.84% and 25.19 ± 2.99% in
APPwt and APPsw cells, respectively. Subsequently, we studied
the involvement of Cdk5 in APP-transfected cell death. First, the
inﬂuence of two Cdk5 inhibitors, Roscovitine and BML-259, on con-
trol cells was analysed to establish the toxicity of the inhibitors.
Fig. 3. The effect of APP transfection on the level of mRNA for the Cdk5 gene. The
level of mRNA for the Cdk5 gene in cell lines PC12, APPwt and APPsw was analysed
using real-time PCR. Data represent the mean value ± S.E.M. for 4–5 independent
experiments.⁄P < 0.05, compared to PC12 cells; #P < 0.05 compared to APPwt cells
using a one-way ANOVA followed by Newman–Keuls test.
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toxic effects on PC12 cells up to a 50 lM concentration (data not
shown). According to previously published data, a concentration
of 10 lM was chosen for further experiments [22]. The incubation
of APP-transfected cells in the presence of 10 lM Roscovitine or
BML-259 had no effect on transfection-evoked cell death as dem-
onstrated in the LDH leakage assay (Fig. 2A) and the MTT reduction
test (Fig. 2B).
3.2. APP-transfection induced an increase in mRNA levels for Cdk5
The analysis of mRNA levels for tested genes was performed
using a quantitative RT-PCR method. Actb, Gusb and Tbp were ana-
lysed as reference genes. No difference in the levels of mRNA for
these genes was observed (data not shown). Actb was selected
and used in all studies. As shown in Fig. 3, the level of mRNA for
the Cdk5 gene was increased by 23% in APPsw cells compared to
control PC12 cells. No signiﬁcant difference was observed in cells
transfected with APPwt. Despite a similar tendency, no statistically
signiﬁcant differences were observed in the levels of mRNA for the
Cdk5r1 gene, which codes the regulatory p35 protein, or Cdk5r2,
which codes the p39 protein (data not shown).
3.3. APP-transfection evoked alterations in protein phosphorylation
To examine the effect of APP transfection on Cdk5, the protein
level and phosphorylation state of this kinase were analysed by
Western blotting (Fig. 4A). As shown in Fig. 4B, the protein levelsFig. 2. The effect of Cdk5 inhibitors on cell viability. The effect of the Cdk5
inhibitors, Roscovitine and BML-259, on cell death was estimated using the LDH
leakage assay, and the effect on cell viability was analysed using the MTT assay.
PC12, APPwt and APPsw cells were incubated in the presence of 10 lM Roscovitine
or BML-259 in low-serum medium for 48 h, and the LDH leakage assay (A) and the
MTT reduction assay (B) were performed as described in Section 2. Data represent
the mean value ± S.E.M. for 3–7 independent experiments. ⁄⁄⁄P < 0.001, compared to
PC12 cells; ##P < 0.01 compared to APPwt cells using a one-way ANOVA followed by
Newman–Keuls test.of Cdk5 were not changed in APP-transfected cells. We did not de-
tect any signiﬁcant differences in the immunoreactivity of a phos-
pho-Cdk5(Ser159)-speciﬁc antibody (Fig. 4C). However, signiﬁcant
differences in immunoreactivity of the phospho-Cdk5(Tyr15)-spe-
ciﬁc antibody were observed, which indicated that the phosphory-
lation of Tyr15 was reduced in APP-transfected cells compared to
control cells (Fig. 4D).
Additionally, we analysed alterations of Cdk5-dependent Gsk-
3b phosphorylation in APP-transfected cells (Fig. 5A). No statisti-
cally signiﬁcant difference was observed in the levels of protein
(Fig. 5B). However, a reduction in the immunoreactivity of phos-
pho-Gsk-3b(Ser9)-speciﬁc antibody was observed in APPsw cells
compared to control cells (Fig. 5C). Treatment of PC12 cells with
the Cdk5 inhibitors, Roscovitine and BML-259, reduced the levels
of phosphorylation of Gsk-3b at Ser9 (data not shown).
Moreover, we analysed the phosphorylation of MAP tau at
Ser396. Signiﬁcant difference in the immunoreactivity of the phos-
pho-MAP tau (Ser396)-speciﬁc antibody was observed, which indi-
cated an increased phosphorylation in APPsw-transfected cells
compared to control cells (Fig. 6).
4. Discussion
Our results support and extend evidence for the involvement of
Cdk5 in Ab-evoked toxicity. The deregulation of Cdk5 activity due
to decreased phosphorylation may be an important mechanism
that leads to the detrimental overactivation of Gsk-3b.
The rat Pheochromocytoma PC12 cell line is of neuronal origin
and is the most widely used model of neuronal cell function and
differentiation [20,23,24]. PC12 cells express functional Cdk5 and
p35/p39 proteins. Our previous studies have indicated that trans-
fection with APP leads to enhanced NO production, the changes
in phosphorylation of cPLA2 and other proteins, arachidonic acid
(AA) release, the activation of the endosomal–lysosomal system
and mitochondrial dysfunction in PC12 cells [25–27].
To evaluate the role of Cdk5 in cells overexpressing APP, we
analysed PC12 cell lines transfected with one of two human APP
genes, the wild-type APP (APPwt cells) or the Swedish double mu-
tant APP (APPsw cells) [28]. Our data indicated that transfection
with APP evoked cell death processes in the PC12 line. In agree-
ment with our expectancy, APPsw cells were more affected than
APPwt cells, which is probably dependent on the level of Ab pep-
tide that was produced. As determined previously, APPwt and
APPsw cell lines released 2.84 and 4.76 times more Ab into the
Fig. 4. The effect of APP transfection on the level and phosphorylation of Cdk5. The total level of protein and phosphorylation of Cdk5 was determined in PC12, APPwt and
APPsw cells using the Western blotting method. (A) Immunoreactivity of Cdk5, phospho-Cdk5(Ser159), phospho-Cdk5(Tyr15) and GAPDH, which is presented as a loading
control. (B) Densitometric analysis of Cdk5 immunoreactivity. (C) Densitometric analysis of phospho-Cdk5(Ser159) immunoreactivity. (D) Densitometric analysis of phospho-
Cdk5(Tyr15) immunoreactivity. Results were normalised to GAPDH levels. Data represent the mean value ± S.E.M. for 3–9 independent experiments. ⁄P < 0.05, compared to
PC12 cells using a one-way ANOVA followed by Newman–Keuls test.
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transfection had no effect on the expression of the rat App gene
(data not shown). Because it has been shown previously that Ab
stimulates Cdk5 activity [29], we tested whether an increased
expression of APP followed by an enhanced intracellular accumula-
tion of Ab may produce the same effect. As shown in Fig. 2, the
Cdk5 inhibitors, Roscovitine and BML-259 at a 10 lM concentra-
tion, did not prevent increased cell death in the APP-expressing cell
lines, which indicated that the increased cell death of APP-express-
ing cells was not evoked by the increased activity of Cdk5. It was
recently demonstrated that Cdk5 activity inversely correlates with
APP expression levels [24]; an increase of Cdk5 activity in the
brains of APP-knock out mice was observed. To evaluate the effect
of the increased APP expression on Cdk5, we studied the expres-
sion and phosphorylation of Cdk5. As shown in Fig. 3, the level of
mRNA for the Cdk5 gene was increased in APPsw cells but not in
APPwt cells. We also did not notice any changes in mRNA levels
for the Cdk5 activators, p35 and p39. A recently published analysis
of global gene expression in human glioblastoma H4 cells stably
transfected with an APP gene bearing the Swedish mutation indi-
cated a 1.89-fold increase of CDK5 gene expression [30]. Our results
do not indicate if Cdk5 gene expression is changed on the level of
transcription or post-transcriptionally. However, we have excluded
the role of FosB and COX-2 in alteration of Cdk5 gene expression in
APP-expressing cells (data not shown) [31–33]. Further studies,
including analysis of the role of miRNA, are necessary to determine
the molecular pathway that induces the enhanced expression of
Cdk5 in APP-transfected cells.
Immunochemical analysis of Cdk5 phosphorylation at Tyr15
and Ser159 indicated pronounced alterations in APP-transfected
cells. A statistically signiﬁcant effect was observed for Tyr15 in
APPwt and APPsw cells. Several kinases may be responsible forCdk5 phosphorylation. Fyn, c-Abl, TrkB, Eph4, HER2 and FGFR1
are upstream Cdk5 kinases responsible for Tyr15 phosphorylation
[34–37]. Also, Protein phosphatase 1 is responsible for Tyr15 site
regulation [36]. However, in AD and in experimental models of
AD, a decrease in the expression and activity of protein phospha-
tases is observed [30,38,39]. A decline of phosphorylation at
Tyr15 indicated that activity of Cdk5 in APP-expressing cells was
decreased, which is in agreement with previously published data
that indicate an increase of Cdk5 activity in APP knockout (KO)
cells [19]. Phosphorylation at Ser159, which may be processed by
Cdk7 and CK1-A, has the same effect on the catalytic activity of
Cdk5. However, we did not ﬁnd any changes in the phosphoryla-
tion of this site.
To verify this observation, the phosphorylation of Gsk-3b at
Ser9 was analysed. As presented previously, this phosphorylation
site is dependent on Cdk5 activity. Morﬁni et al. [40] have identi-
ﬁed a pathway that links the activity of Cdk5 and Gsk-3b that is
dependent on the phosphorylation state of Ser9. Moreover, p25-
overexpressing mice have an enhanced Cdk5 activity and a re-
duced Gsk-3b activity that is attributable to phosphorylation at
the inhibitory Ser9 of Gsk-3b [41]. In addition, the pharmacological
inhibition of Cdk5 with CP-681301 reduces the phosphorylation le-
vel of Gsk-3b(Ser9) [41]. In accordance to a decrease in Cdk5 activ-
ity, the phosphorylation of Gsk-3b at Ser9 in APP-expressing cell
lines was decreased. The activity of Gsk-3b is regulated mainly
by the phosphorylation of Ser9. Phosphorylation inhibits Gsk-3b
and dephosphorylation, by PPP1CA or laforin, leads to a potent in-
crease in activity. Our data indicated that the activity of Gsk-3b
may be increased in APP-transfected cells. The consequences of
Gsk-3b overactivation may be the hyperphosphorylation of target
proteins, including MAP tau. To conﬁrm the relationship between
Cdk5 activity and the phosphorylation of Ser9 in Gsk-3b, we
Fig. 5. The effect of APP transfection on the level and phosphorylation of Gsk-3b.
The total level of protein and phosphorylation of Gsk-3b was determined in PC12,
APPwt and APPsw cells using theWestern blotting method. (A) Immunoreactivity of
Gsk-3b, phospho-Gsk-3b(Ser9) and GAPDH, which is presented as a loading control.
(B) Densitometric analysis of Gsk-3b immunoreactivity. (C) Densitometric analysis
of phospho-Gsk-3b(Ser9) immunoreactivity. Results were normalised to GAPDH
levels. Data represent the mean value ± S.E.M. for 3 independent experiments.
⁄P < 0.05, compared to PC12 cells using a one-way ANOVA followed by Newman–
Keuls test.
Fig. 6. The effect of APP transfection on the level and phosphorylation of MAP tau.
(A) The level of phosphorylation of MAP tau (Ser396) was determined in PC12,
APPwt and APPsw cells using the Western blotting method. Actin is presented as a
loading control. (B) Densitometric analysis of phospho-MAP tau (Ser396) immu-
noreactivity. Results were normalised to Actin levels. Data represent the mean
value ± S.E.M. for 3 independent experiments. ⁄P < 0.05, compared to PC12 cells
using a one-way ANOVA followed by Newman–Keuls test.
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259, on Gsk-3b phosphorylation in PC12 cells. The decreased levels
of phospho-Gsk-3b(Ser9) immunoreactivity in Cdk5 inhibitor-trea-
ted cells indicated that the phosphorylation of Ser9 was dependent
on Cdk5 activity. To conﬁrm the link between Cdk5 activity, the
phosphorylation of Ser9 in Gsk-3b, and Gsk-3b activity, we ana-lysed the phosphorylation of MAP tau at Ser396, the site dependent
on Gsk-3b. Signiﬁcant increase of MAP tau phosphorylation at
Ser396 indicated that Gsk-3b activity was increased in APPsw-
transfected cells, compared to control cells.
Our study demonstrated for the ﬁrst time deregulation of Cdk5
in PC12 cells that overexpressed human APP. Despite this increased
expression, the activity of Cdk5 was reduced in APP-transfected
cells due to a decreased phosphorylation at Tyr15. Cdk5-dependent
phosphorylation of Gsk-3b at Ser9 was also reduced, which may
lead to the deleterious overactivation of Gsk-3b. The PI3K-Akt sig-
naling cascade has been the best-studied mechanism of Ab-depen-
dent GSK-3b overactivation. However, both Cdk5 and Gsk-3b are at
the centre of research on AD. These two kinases have been impli-
cated in the pathogenic processes related to MAP tau hyper-
phosphorylation and APP processing. Recently, it has been
suggested that Cdk5 is the predominant kinase that regulates
APP processing, and GSK-3b is the main kinase that is responsible
for the hyperphosphorylation of MAP tau [41]. Tau is a microtu-
bule-associated protein that is expressed mainly in neurons and
is involved in the assembly and stabilisation of the neuronal micro-
tubules network [42]. Tau hyperphosphorylation, which is signiﬁ-
cantly increased in AD brains, leads to the formation of
neuroﬁbrillary tangles (NFT), the amounts of which correlate
greatly with the severity of dementia in AD [43]. An understanding
of the role of the crosstalk between Cdk5 and Gsk-3b is necessary
for a clariﬁcation of the mechanisms of tau hyperphosphorylation
in AD. Our ﬁndings revealed a novel pathway of Ab-evoked dereg-
ulation of this phosphorylation cascade, which led to increased
phosphorylation due to the overactivation of Gsk-3b.
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